Nucleai Unveils Breakthrough AI Spatial Biomarker Advancements At AACR 2024
Nucleai, a spatial AI biomarker company, is set to present its cutting-edge developments in cancer research and diagnostics at the AACR Annual Meeting in San Diego from April 5-10, 2024. Their posters will unveil novel AI spatial biomarkers and advanced histopathology workflows, promising to revolutionize cancer treatment and diagnostics. In collaboration with Dr. Arutha Kulasinghe, Nucleai's first poster reveals a groundbreaking signature linked to immunotherapy outcomes in lung cancer. Leveraging their unique AI spatial biology solution, the research uncovers correlations between metabolic states and spatial distribution of cells, offering crucial insights into disease progression and treatment response. Their second poster introduces the H&E 2.0 algorithm, a significant leap in cancer pathology that automates tasks and improves accuracy, marking a stride toward more precise diagnosis and treatment. Driven by innovation, Nucleai integrates spatial biology with AI to extract actionable insights from pathology data, setting a new standard for precision medicine and enhancing patient care. Visit nucleai.ai/aacr2024 for more details on their AACR presence.
Read More - https://www.techdogs.com/tech-news/business-wire/nucleai-unveils-breakthrough-ai-spatial-biomarker-advancements-at-aacr-2024-with-the-potential-to-transform-cancer-diagnostics-and-treatments

Comments
Post a Comment